Vodafone and UK-based pharmaceutical company AstraZeneca have announced a global partnership that’ll see them using mobile health services to help patients with cardiovascular conditions.
The collaboration will work in partnership with healthcare professionals, who’ll enable patients to use mobile and internet-based mHealth services during their treatment. This will enable the patients to manage their condition, track their treatment and monitor their medication via a smartphone or web browser.
AstraZeneca’s Intelligent Pharmaceutical Group will lead the project, with Vodafone providing the technology, infrastructure and expertise.
Erik Brenneis, Vodafone’s Director for Machine to Machine, said “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services.”